Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769608 · ClinicalTrials.gov registry record · Phase 2
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A Phase 2 study of Hypertension, sponsored by Mineralys Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
- 20
- Study locations
NCT05769608: Completed Phase 2 study of Hypertension, sponsored by Mineralys Therapeutics.
NCT05769608 is a Phase 2 study of Hypertension that has completed, run by Mineralys Therapeutics. The registered enrollment target is 285 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05769608, a Phase 2 study of Hypertension, has completed, sponsored by Mineralys Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG lorundrostat Dose 1
- DRUG lorundrostat Dose 2
Study Locations (20)
California
- The Medical Research Group Inc. - Fresno
- Marvel Clinical Research - Huntington Beach
- University of California San Diego (UCSD) - Altman Clinical and Translational Research Institute (ACTRI) - La Jolla
- Clinical Trials Research - Lincoln
- Cedars-Sinai Medical Center - Los Angeles
- Catalina Research Institute - Montclair
- Northridge Clinical Trials - Northridge
- University of California Irvine Medical Center - Orange
- Triwest Research Associates - San Diego
- San Jose Clinical Trials - San Jose
- Blue Coast Research Center - Vista
- Accelerated Enrollment Solutions (AES)- Vista - Vista
Arizona
- Chandler Clinical Trials - Chandler
- Brown Road Family Medicine - Mesa
- Scottsdale Clinical Trials (Elite Clinical Network) - Scottsdale
- Fiel Family & Sports Medicine - Tempe
- Noble Clinical Research - Tucson
- Del Sol Research Management, LLC - Tucson
Alabama
- Cardiology, P.C. - Birmingham - Birmingham
- University of Alabama at Birmingham (UAB) - Vascular Biology and Hypertension Program - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 2 |
What the finished NCT05769608 record still lists
NCT05769608 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05769608 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT05769608 about?
NCT05769608 is a clinical study titled "A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen". A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.
What is the current status of trial NCT05769608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2023-03-13. Estimated completion is 2025-01-15.
What conditions does trial NCT05769608 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT05769608?
The interventions under investigation include: Placebo (DRUG), lorundrostat Dose 1 (DRUG), lorundrostat Dose 2 (DRUG).
Who is sponsoring clinical trial NCT05769608?
This trial is sponsored by Mineralys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05769608 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05769608's enrollment target sits among peer trials
285 184th of 470 higher than 287 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI